name,reason,comment,source
OXYBUTYNIN,toxic,"In particular, oxybutynin has consistently been shown to cause deterioration in memory",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734922/
RISPERIDONE,studied,This retrospective study demonstrates that risperidone appears to be efficacious in the treatment of clinically significant positive and negative symptoms in patients with AD.,https://pubmed.ncbi.nlm.nih.gov/11263718/
TELMISARTAN,studied,Researchers believe telmisartan can slow the progression of Alzheimer’s by controlling blood flow,https://www.alzheimers.gov/clinical-trials/telmisartan-prevent-alzheimers-african-americans
BEXAROTENE,studied,Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer´s disease,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223578
PROGESTERONE,natural product,,
CLOTRIMAZOLE,studied,"MCZ treatment significantly attenuated cognitive impairment, suppressed iNOS and cyclooxygenase-2 expression, and activation of astrocyte and microglial BV2 cells",https://www.nature.com/articles/s41419-020-2619-5
CHOLECALCIFEROL,natural product,,
SUVOREXANT,studied,FDA approved for insomnia in AD,https://www.neurologylive.com/view/suvorexant-now-indicated-for-treatment-of-insomnia-in-alzheimer-disease
AGOMELATINE,studied,"Agomelatine is effective on improving behavioral and psychological symptoms of dementia, no matter in depression, sleep disturbance, delusion, hallucination, or aggression",https://www.ajgponline.org/article/S1064-7481(19)30145-9/abstract
DROPERIDOL,unsuitable,Commonly given as sedative in emergency medicine,https://medicalxpress.com/news/2021-04-droperidol-effective-sedation-medication-agitation.html
RIMONABANT,unsuitable,"Associated with an increased risk of anxiety, depression, and suicide.",https://www.nature.com/articles/nrcardio.2010.148
AMOXAPINE,studied,"Taken together, our study suggests that amoxapine, though no longer a first-line drug for the treatment of depression, may be beneficial for AD",https://www.nature.com/articles/s41598-017-04144-3
NORETHINDRONE,natural product,,
LEUPROLIDE,studied,These data indicate that cognitive function is preserved in patients treated with high dose Lupron who were already using AChEIs. The positive interaction between Lupron and AChEIs warrants further investigation for the treatment of AD.,https://pubmed.ncbi.nlm.nih.gov/25310993/
BENZTROPINE,unsuitable,A robust association between some classes of anticholinergic drugs and future dementia incidence was observed.,https://www.bmj.com/content/361/bmj.k1315
ROSIGLITAZONE,studied,Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535054/
CLOSANTEL,unsuitable,Toxic,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129234/
MIFEPRISTONE,studied,Failed AD trial,https://www.clinicaltrials.gov/ct2/show/study/NCT00105105
PREDNISOLONE,studied,Failed AD trial,https://pubmed.ncbi.nlm.nih.gov/11061280/
PENTAGASTRIN,natural product,,
ESTRADIOL,natural product,,
LIOTHYRONINE,natural product,,
SOMATOSTATIN,natural product,,
FASIGLIFAM,unsuitable,Liver toxicity,https://www.fiercebiotech.com/biotech/takeda-announces-termination-of-fasiglifam-tak-875-development
MURAGLITAZAR,unsuitable,Adverse events in trials,https://jamanetwork.com/journals/jama/fullarticle/201927
SILDENAFIL,studied,Trials in the making,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242821/
PRANLUKAST,studied,Trial of close analog MONTELUKAST in progress,https://www.alzheimers.gov/clinical-trials/montelukast-therapy-alzheimers-disease
TARANABANT,unsuitable,Serious CNS side effects,https://blogs.sciencemag.org/pipeline/archives/2008/03/12/taranabant_in_trouble
TELCAGEPANT,unsuitable,Liver toxicity,https://www.clinicaltrials.gov/ct2/show/NCT00797667
PROPRANOLOL,studied,"Overall, these data further strengthen the potential of propranolol as a therapeutic agent for AD.",https://academic.oup.com/ijnp/article/16/10/2245/653042
SEGLITIDE,unsuitable,Serious side effects,https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/seglitide
KISSPEPTIN-10,studied,"These results suggest that KP peptides are neuroprotective against Aβ, IAPP, and PrP peptides via a receptor independent action involving direct binding to the amyloid peptides.",https://pubs-acs-org.ezp-prod1.hul.harvard.edu/doi/full/10.1021/cn300045d
SEROTONIN,natural product,,
OXYTOCIN,natural product,,
DIETHYLSTILBESTROL,natural product,,
CLOZAPINE,studied,"This study suggests that as one of candidate for multi-target approach of AD treatment, clozapine is proposed as a therapeutic drug for treatment of AD patients.",https://pubmed.ncbi.nlm.nih.gov/26742522/
ISTRADEFYLLINE,studied,"Moreover, in amyloid plaque-bearing mice, low-dose istradefylline treatment enhanced spatial memory and habituation",https://pubmed.ncbi.nlm.nih.gov/29100987/
ERGOTAMINE,studied,This study offers DHEC not only as a new chemical moiety for selectively modulating the activity of γ-secretase but also a candidate for drug repositioning in Alzheimer’s disease.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644980/
MELATONIN,natural product,,
ALMOREXANT,unsuitable,Potential liver toxicity,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086961/
BROMOCRIPTINE,studied,AD clinical trial in progress,https://clinicaltrials.gov/ct2/show/NCT04413344
BUPRENORPHINE,unsuitable,Addictive opioid,https://drugfree.org/drugs/prescription-pain-relievers-opioids
ROLOFYLLINE,unsuitable,Seizures and stroke in trial,https://www.medscape.com/viewarticle/708267
HALOPERIDOL,studied,Haloperidol (2–3 mg/d) decreased psychosis and disruptive behaviours in Alzheimer's disease although 20% of patients developed moderate to severe extrapyramidal side effects.,https://ebmh.bmj.com/content/2/2/48
NIACIN,natural product,,
ZAFIRLUKAST,studied,Trial of close analog MONTELUKAST in progress,https://www.alzheimers.gov/clinical-trials/montelukast-therapy-alzheimers-disease
ALFUZOSIN,studied,The results suggest that tamsulosin for BPH is not associated with worsening of the cognitive decline in patients with AD.,https://journals.lww.com/md-journal/fulltext/2020/05290/the_impact_of_tamsulosin_on_cognition_in_alzheimer.34.aspx
MEDROXYPROGESTERONE ACETATE,natural product,,
CARVEDILOL,studied,AD clinical trial in progress,https://www.clinicaltrials.gov/ct2/show/NCT01354444
MONTELUKAST,studied,AD clinical trial in progress,https://www.alzheimers.gov/clinical-trials/montelukast-therapy-alzheimers-disease
HISTAMINE,natural product,,